There’s been a substantial proof psychedelics can help with issues such as depression, anxiety, addiction, obsessive compulsive disorder, and obesity.
Exploring the companies and themes that make up this emerging and exciting new sector
Texas Closer to Passing Bill That Studies Medicinal Psychoactive Drugs
The bill passed 6-0 and has garnered bipartisan support.
Health Official Touts Psilocybin's’ Therapeutic Benefits
A top U.S. health official on Wednesday touted the therapeutic potential of psychedelics like psilocybin and MDMA.
MindMed Announces Launch of Collaboration with Nextage Therapeutics' Brain Targeting Liposome System
MindMed executes an MOU to access the drug delivery system of Israel-based Nextage Therapeutics.
Biotech revolution on horizon could change mental health treatment
There’s a psychedelic revolution on the horizon that could change mental health treatment.
Robust Capital Flows Continue For Private Psychedelics Companies
Public psychedelics companies have radically scaled-back capital raising due to low share prices. But institutional investors are still pumping large amounts of cash into private players.
Wesana Health Expands Research Leadership Team with Mark Wingertzahn, PhD as Chief Scientific Officer
Wesana's new Chief Scientific Officer has deep experience in the pharmaceutical industry with Pfizer and GSK.
Former Senate Majority Leader Tom Daschle Appointed Special Adviser to Field Trip Health Ltd.
Field Trip appoints a former high-ranking Democrat as a Special Advisor to the company.
Use of hallucinogens linked to risk seeking, emotional dysregulation in youth and college students
Hallucinogens benefit from somewhat greater acceptance than many other hard drugs, no doubt due in part to the fact that classic hallucinogens like LSD tend to be less harmful and are less likely to lead to physical dependence.
Cybin Files its 12th Patent Further Strengthening IP Portfolio of Novel Psychedelic Molecules and Delivery Mechanisms
Cybin's 12th patent application further supports the company's novel molecule development.
MindMed Announces the Approval of Mescaline Study
Mindmed's drug R&D is broadening to include mescaline, after approval by a Swiss ethics committee of a new mescaline-based study.
Dr. Joel Raskin, a leader in psychiatry and neuroscience drug development, joins MINDCURE as Chief Medical Officer
MINDCURE announces the addition of Dr. Joel Raskin as its new Chief Medical Officer. Experience includes leadership positions with drug developer, Eli Lilly & Co.